Pharmaceutical Business review

DSM Q1 Net Sales Up 21%

DSM posted a net income of EUR130m for the first quarter 2010, or EUR0.78 per diluted share, compared to EUR13m, or EUR0.06 per diluted share, for the prior year period. Operating income was EUR218m, compared to EUR57m for the year ago period.

Feike Sijbesma, chairman of the managing board at DSM, said: “I am pleased to report that DSM has delivered a very strong start to 2010. Operating profit from our core businesses is not only up very strongly compared to Q1 2009, it has also returned to the level achieved in Q1 2008.

“Whilst uncertainties remain in the medium term economic outlook, the strong Q1

result and continued positive business conditions give us confidence that 2010 will be a good year for DSM.”